Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31035604 | 0.83 | PTPN1 (0.45) | PTPN1ESR1ESR2MAOBCSNK2A2 | |
| SCHEMBL23887130 | 0.78 | PTPN1 (0.72) | PTPN1MAOBALDH1A1MAOA | |
| SCHEMBL20906139 | 0.75 | HTT (0.32) | PTPN1ESR1ESR2MAPT | |
| SCHEMBL30940310 | 0.74 | PTPN1 (0.45) | PTPN1MAOBALDH1A1MAPTMAOA | |
| SCHEMBL28990300 | 0.72 | LOXL2 (0.36) | PTPN1MAOBALDH1A1MAPTMAOA | |
| SCHEMBL30940293 | 0.69 | ALDH1A1 (0.40) | ESR1ESR2MAOBCSNK2A2CSNK2B | |
| SCHEMBL29116198 | 0.69 | ALDH1A1 (0.55) | PTPN1MAOBALDH1A1MAPTMAOA | |
| SCHEMBL11539348 | 0.69 | PTPN1 (0.61) | PTPN1ESR1ESR2MAOBCSNK2A2 | |
| SCHEMBL27313611 | 0.67 | ATM (0.35) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL31035336 | 0.66 | ESR1 (0.40) | ESR1ESR2MAOBCSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117693506-A | Allosteric ketone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230017140-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | PTPN1 597/4885ESR1 446/4885ESR2 721/4885 |
| US-20230017140-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PTPN1 597/4885ESR1 446/4885ESR2 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.